Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MODERN: MRD-guided adjuvant nivolumab, with or without relatlimab, in urothelial cancer

Alliance A032103 randomizes patients after surgery for muscle-invasive urothelial cancer of the bladder, renal pelvis, ureter, or urethra according to ctDNA, escalating MRD-positive patients to nivolumab plus relatlimab versus nivolumab and comparing surveillance with nivolumab in MRD-negative patients.

National Cancer Institute